72
Participants
Start Date
October 13, 2021
Primary Completion Date
December 30, 2024
Study Completion Date
December 30, 2024
Vemurafenib
960 mg twice daily during run-in Phase, followed by 720 mg twice daily
Cobimetinib
60 mg once daily
Atezolizumab
840 mg every 2 weeks
Trastuzumab
8 mg per kilogram of body weight as a loading dose, followed by 6 mg per kilogram every 3 weeks
Pertuzumab
840 mg as a loading dose, followed by 420 mg intravenously every 3 weeks
Alectinib
600 mg twice daily
Ipatasertib
400 mg once daily
Atezolizumab
1200 mg every 3 weeks
Atezolizumab
1200 mg in the first cycle, followed by 840 mg every 3 weeks
Atezolizumab
1,200 mg every 3 weeks
Inavolisib
9 mg once daily
Charité - Universitätsmedizin Berlin, Berlin
Universitätsklinikum Schleswig-Holstein, Lübeck
Universitätsmedizin der Johannes Gutenberg- Universität Mainz, Mainz
Nationales Centrum für Tumorerkrankungen (NCT), Heidelberg
Universitätsklinikum Tübingen, Medizinische Klinik I, Tübingen
Universitätsklinikum Freiburg, Freiburg im Breisgau
Klinikum Rechts der Isar der TU München, München
Universitätsklinikum Würzburg, Interdisziplinäres Studienzentrum mit ECTU, Würzburg
Nationales Centrum für Tumorerkrankungen (NCT), Dresden
German Cancer Research Center
OTHER